| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
52 |
| Employees |
125 |
| Revenues (TTM) (Millions $) |
82 |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
55 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Jounce Therapeutics Inc.
is a clinical-stage immunotherapy company that utilizes the latest insights in immunology to develop transformative cancer therapies.
The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Jounce Therapeutics utilizes its proprietary technology to develop cancer immunotherapies that target the tumor microenvironment, rather than the cancer cells themselves.
Its lead product candidate, JTX-2011, is a monoclonal antibody that targets the receptor LILRB4, a checkpoint regulator expressed on immune cells in the tumor microenvironment.
This product candidate is currently being evaluated in clinical trials in patients with advanced solid tumors.
The company also has a preclinical pipeline of potential immunotherapy candidates targeting other checkpoint regulators, including ICOS and B7-H3, as well as new targets.
Jounce Therapeutics has formed partnerships with other biotech and pharmaceutical companies, including Celgene and Gilead, to advance its research and development efforts.
The companyes goal is to provide effective and safe cancer therapies that improve outcomes for patients with solid tumors.
Company Address: 780 Memorial Drive Cambridge, 2139 MA
Company Phone Number: 259‑3840 Stock Exchange / Ticker: NASDAQ JNCE
|
%